JP2016526564A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016526564A5 JP2016526564A5 JP2016524767A JP2016524767A JP2016526564A5 JP 2016526564 A5 JP2016526564 A5 JP 2016526564A5 JP 2016524767 A JP2016524767 A JP 2016524767A JP 2016524767 A JP2016524767 A JP 2016524767A JP 2016526564 A5 JP2016526564 A5 JP 2016526564A5
- Authority
- JP
- Japan
- Prior art keywords
- compound
- formula
- general formula
- here
- galap
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000012634 fragment Substances 0.000 claims 30
- -1 monosaccharide disulfide Chemical class 0.000 claims 27
- 125000006239 protecting group Chemical group 0.000 claims 21
- 150000001875 compounds Chemical class 0.000 claims 18
- 241000193998 Streptococcus pneumoniae Species 0.000 claims 17
- 229940031000 streptococcus pneumoniae Drugs 0.000 claims 15
- 238000006243 chemical reaction Methods 0.000 claims 13
- 150000001720 carbohydrates Chemical class 0.000 claims 11
- 230000015572 biosynthetic process Effects 0.000 claims 8
- 239000003638 chemical reducing agent Substances 0.000 claims 8
- 238000003786 synthesis reaction Methods 0.000 claims 8
- 229940125782 compound 2 Drugs 0.000 claims 7
- DLFVBJFMPXGRIB-UHFFFAOYSA-N Acetamide Chemical group CC(N)=O DLFVBJFMPXGRIB-UHFFFAOYSA-N 0.000 claims 6
- IVRMZWNICZWHMI-UHFFFAOYSA-N azide group Chemical group [N-]=[N+]=[N-] IVRMZWNICZWHMI-UHFFFAOYSA-N 0.000 claims 6
- 238000003776 cleavage reaction Methods 0.000 claims 6
- 150000002016 disaccharides Chemical class 0.000 claims 6
- 230000007017 scission Effects 0.000 claims 6
- UAOUIVVJBYDFKD-XKCDOFEDSA-N (1R,9R,10S,11R,12R,15S,18S,21R)-10,11,21-trihydroxy-8,8-dimethyl-14-methylidene-4-(prop-2-enylamino)-20-oxa-5-thia-3-azahexacyclo[9.7.2.112,15.01,9.02,6.012,18]henicosa-2(6),3-dien-13-one Chemical compound C([C@@H]1[C@@H](O)[C@@]23C(C1=C)=O)C[C@H]2[C@]12C(N=C(NCC=C)S4)=C4CC(C)(C)[C@H]1[C@H](O)[C@]3(O)OC2 UAOUIVVJBYDFKD-XKCDOFEDSA-N 0.000 claims 5
- 229940126214 compound 3 Drugs 0.000 claims 5
- 239000000203 mixture Substances 0.000 claims 5
- GHYOCDFICYLMRF-UTIIJYGPSA-N (2S,3R)-N-[(2S)-3-(cyclopenten-1-yl)-1-[(2R)-2-methyloxiran-2-yl]-1-oxopropan-2-yl]-3-hydroxy-3-(4-methoxyphenyl)-2-[[(2S)-2-[(2-morpholin-4-ylacetyl)amino]propanoyl]amino]propanamide Chemical compound C1(=CCCC1)C[C@@H](C(=O)[C@@]1(OC1)C)NC([C@H]([C@@H](C1=CC=C(C=C1)OC)O)NC([C@H](C)NC(CN1CCOCC1)=O)=O)=O GHYOCDFICYLMRF-UTIIJYGPSA-N 0.000 claims 4
- ONBQEOIKXPHGMB-VBSBHUPXSA-N 1-[2-[(2s,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]oxy-4,6-dihydroxyphenyl]-3-(4-hydroxyphenyl)propan-1-one Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1OC1=CC(O)=CC(O)=C1C(=O)CCC1=CC=C(O)C=C1 ONBQEOIKXPHGMB-VBSBHUPXSA-N 0.000 claims 4
- UNILWMWFPHPYOR-KXEYIPSPSA-M 1-[6-[2-[3-[3-[3-[2-[2-[3-[[2-[2-[[(2r)-1-[[2-[[(2r)-1-[3-[2-[2-[3-[[2-(2-amino-2-oxoethoxy)acetyl]amino]propoxy]ethoxy]ethoxy]propylamino]-3-hydroxy-1-oxopropan-2-yl]amino]-2-oxoethyl]amino]-3-[(2r)-2,3-di(hexadecanoyloxy)propyl]sulfanyl-1-oxopropan-2-yl Chemical compound O=C1C(SCCC(=O)NCCCOCCOCCOCCCNC(=O)COCC(=O)N[C@@H](CSC[C@@H](COC(=O)CCCCCCCCCCCCCCC)OC(=O)CCCCCCCCCCCCCCC)C(=O)NCC(=O)N[C@H](CO)C(=O)NCCCOCCOCCOCCCNC(=O)COCC(N)=O)CC(=O)N1CCNC(=O)CCCCCN\1C2=CC=C(S([O-])(=O)=O)C=C2CC/1=C/C=C/C=C/C1=[N+](CC)C2=CC=C(S([O-])(=O)=O)C=C2C1 UNILWMWFPHPYOR-KXEYIPSPSA-M 0.000 claims 4
- 241000894006 Bacteria Species 0.000 claims 4
- LJOOWESTVASNOG-UFJKPHDISA-N [(1s,3r,4ar,7s,8s,8as)-3-hydroxy-8-[2-[(4r)-4-hydroxy-6-oxooxan-2-yl]ethyl]-7-methyl-1,2,3,4,4a,7,8,8a-octahydronaphthalen-1-yl] (2s)-2-methylbutanoate Chemical compound C([C@H]1[C@@H](C)C=C[C@H]2C[C@@H](O)C[C@@H]([C@H]12)OC(=O)[C@@H](C)CC)CC1C[C@@H](O)CC(=O)O1 LJOOWESTVASNOG-UFJKPHDISA-N 0.000 claims 4
- XRWSZZJLZRKHHD-WVWIJVSJSA-N asunaprevir Chemical compound O=C([C@@H]1C[C@H](CN1C(=O)[C@@H](NC(=O)OC(C)(C)C)C(C)(C)C)OC1=NC=C(C2=CC=C(Cl)C=C21)OC)N[C@]1(C(=O)NS(=O)(=O)C2CC2)C[C@H]1C=C XRWSZZJLZRKHHD-WVWIJVSJSA-N 0.000 claims 4
- KGNDCEVUMONOKF-UGPLYTSKSA-N benzyl n-[(2r)-1-[(2s,4r)-2-[[(2s)-6-amino-1-(1,3-benzoxazol-2-yl)-1,1-dihydroxyhexan-2-yl]carbamoyl]-4-[(4-methylphenyl)methoxy]pyrrolidin-1-yl]-1-oxo-4-phenylbutan-2-yl]carbamate Chemical compound C1=CC(C)=CC=C1CO[C@H]1CN(C(=O)[C@@H](CCC=2C=CC=CC=2)NC(=O)OCC=2C=CC=CC=2)[C@H](C(=O)N[C@@H](CCCCN)C(O)(O)C=2OC3=CC=CC=C3N=2)C1 KGNDCEVUMONOKF-UGPLYTSKSA-N 0.000 claims 4
- 229940125797 compound 12 Drugs 0.000 claims 4
- 229940126142 compound 16 Drugs 0.000 claims 4
- 229940125810 compound 20 Drugs 0.000 claims 4
- 229940125833 compound 23 Drugs 0.000 claims 4
- 229940125961 compound 24 Drugs 0.000 claims 4
- 229940127204 compound 29 Drugs 0.000 claims 4
- 238000010511 deprotection reaction Methods 0.000 claims 4
- 201000010099 disease Diseases 0.000 claims 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 4
- JAXFJECJQZDFJS-XHEPKHHKSA-N gtpl8555 Chemical compound OC(=O)C[C@H](N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N1CCC[C@@H]1C(=O)N[C@H](B1O[C@@]2(C)[C@H]3C[C@H](C3(C)C)C[C@H]2O1)CCC1=CC=C(F)C=C1 JAXFJECJQZDFJS-XHEPKHHKSA-N 0.000 claims 4
- 150000002772 monosaccharides Chemical class 0.000 claims 4
- 239000008194 pharmaceutical composition Substances 0.000 claims 4
- 150000003839 salts Chemical class 0.000 claims 4
- ABJSOROVZZKJGI-OCYUSGCXSA-N (1r,2r,4r)-2-(4-bromophenyl)-n-[(4-chlorophenyl)-(2-fluoropyridin-4-yl)methyl]-4-morpholin-4-ylcyclohexane-1-carboxamide Chemical compound C1=NC(F)=CC(C(NC(=O)[C@H]2[C@@H](C[C@@H](CC2)N2CCOCC2)C=2C=CC(Br)=CC=2)C=2C=CC(Cl)=CC=2)=C1 ABJSOROVZZKJGI-OCYUSGCXSA-N 0.000 claims 3
- GLGNXYJARSMNGJ-VKTIVEEGSA-N (1s,2s,3r,4r)-3-[[5-chloro-2-[(1-ethyl-6-methoxy-2-oxo-4,5-dihydro-3h-1-benzazepin-7-yl)amino]pyrimidin-4-yl]amino]bicyclo[2.2.1]hept-5-ene-2-carboxamide Chemical compound CCN1C(=O)CCCC2=C(OC)C(NC=3N=C(C(=CN=3)Cl)N[C@H]3[C@H]([C@@]4([H])C[C@@]3(C=C4)[H])C(N)=O)=CC=C21 GLGNXYJARSMNGJ-VKTIVEEGSA-N 0.000 claims 3
- SZUVGFMDDVSKSI-WIFOCOSTSA-N (1s,2s,3s,5r)-1-(carboxymethyl)-3,5-bis[(4-phenoxyphenyl)methyl-propylcarbamoyl]cyclopentane-1,2-dicarboxylic acid Chemical compound O=C([C@@H]1[C@@H]([C@](CC(O)=O)([C@H](C(=O)N(CCC)CC=2C=CC(OC=3C=CC=CC=3)=CC=2)C1)C(O)=O)C(O)=O)N(CCC)CC(C=C1)=CC=C1OC1=CC=CC=C1 SZUVGFMDDVSKSI-WIFOCOSTSA-N 0.000 claims 3
- IWZSHWBGHQBIML-ZGGLMWTQSA-N (3S,8S,10R,13S,14S,17S)-17-isoquinolin-7-yl-N,N,10,13-tetramethyl-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-3-amine Chemical compound CN(C)[C@H]1CC[C@]2(C)C3CC[C@@]4(C)[C@@H](CC[C@@H]4c4ccc5ccncc5c4)[C@@H]3CC=C2C1 IWZSHWBGHQBIML-ZGGLMWTQSA-N 0.000 claims 3
- TVTJUIAKQFIXCE-HUKYDQBMSA-N 2-amino-9-[(2R,3S,4S,5R)-4-fluoro-3-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-7-prop-2-ynyl-1H-purine-6,8-dione Chemical compound NC=1NC(C=2N(C(N(C=2N=1)[C@@H]1O[C@@H]([C@H]([C@H]1O)F)CO)=O)CC#C)=O TVTJUIAKQFIXCE-HUKYDQBMSA-N 0.000 claims 3
- NPRYCHLHHVWLQZ-TURQNECASA-N 2-amino-9-[(2R,3S,4S,5R)-4-fluoro-3-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-7-prop-2-ynylpurin-8-one Chemical compound NC1=NC=C2N(C(N(C2=N1)[C@@H]1O[C@@H]([C@H]([C@H]1O)F)CO)=O)CC#C NPRYCHLHHVWLQZ-TURQNECASA-N 0.000 claims 3
- OAKJQQAXSVQMHS-UHFFFAOYSA-N Hydrazine Chemical compound NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 claims 3
- 229940126543 compound 14 Drugs 0.000 claims 3
- 229940125758 compound 15 Drugs 0.000 claims 3
- 229940125851 compound 27 Drugs 0.000 claims 3
- 239000000543 intermediate Substances 0.000 claims 3
- 239000003880 polar aprotic solvent Substances 0.000 claims 3
- 150000004043 trisaccharides Chemical class 0.000 claims 3
- STBLNCCBQMHSRC-BATDWUPUSA-N (2s)-n-[(3s,4s)-5-acetyl-7-cyano-4-methyl-1-[(2-methylnaphthalen-1-yl)methyl]-2-oxo-3,4-dihydro-1,5-benzodiazepin-3-yl]-2-(methylamino)propanamide Chemical compound O=C1[C@@H](NC(=O)[C@H](C)NC)[C@H](C)N(C(C)=O)C2=CC(C#N)=CC=C2N1CC1=C(C)C=CC2=CC=CC=C12 STBLNCCBQMHSRC-BATDWUPUSA-N 0.000 claims 2
- KQZLRWGGWXJPOS-NLFPWZOASA-N 1-[(1R)-1-(2,4-dichlorophenyl)ethyl]-6-[(4S,5R)-4-[(2S)-2-(hydroxymethyl)pyrrolidin-1-yl]-5-methylcyclohexen-1-yl]pyrazolo[3,4-b]pyrazine-3-carbonitrile Chemical compound ClC1=C(C=CC(=C1)Cl)[C@@H](C)N1N=C(C=2C1=NC(=CN=2)C1=CC[C@@H]([C@@H](C1)C)N1[C@@H](CCC1)CO)C#N KQZLRWGGWXJPOS-NLFPWZOASA-N 0.000 claims 2
- WZZBNLYBHUDSHF-DHLKQENFSA-N 1-[(3s,4s)-4-[8-(2-chloro-4-pyrimidin-2-yloxyphenyl)-7-fluoro-2-methylimidazo[4,5-c]quinolin-1-yl]-3-fluoropiperidin-1-yl]-2-hydroxyethanone Chemical compound CC1=NC2=CN=C3C=C(F)C(C=4C(=CC(OC=5N=CC=CN=5)=CC=4)Cl)=CC3=C2N1[C@H]1CCN(C(=O)CO)C[C@@H]1F WZZBNLYBHUDSHF-DHLKQENFSA-N 0.000 claims 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 claims 2
- 229940126639 Compound 33 Drugs 0.000 claims 2
- UDCDOJQOXWCCSD-UHFFFAOYSA-N N,N-dimethyl-N'-p-tolylsulfamide Chemical compound CN(C)S(=O)(=O)NC1=CC=C(C)C=C1 UDCDOJQOXWCCSD-UHFFFAOYSA-N 0.000 claims 2
- 229930182473 O-glycoside Natural products 0.000 claims 2
- PNUZDKCDAWUEGK-CYZMBNFOSA-N Sitafloxacin Chemical compound C([C@H]1N)N(C=2C(=C3C(C(C(C(O)=O)=CN3[C@H]3[C@H](C3)F)=O)=CC=2F)Cl)CC11CC1 PNUZDKCDAWUEGK-CYZMBNFOSA-N 0.000 claims 2
- 230000001580 bacterial effect Effects 0.000 claims 2
- 229940125877 compound 31 Drugs 0.000 claims 2
- 229940125878 compound 36 Drugs 0.000 claims 2
- 150000004676 glycans Chemical class 0.000 claims 2
- 230000003053 immunization Effects 0.000 claims 2
- 238000002649 immunization Methods 0.000 claims 2
- 239000012454 non-polar solvent Substances 0.000 claims 2
- 229920001282 polysaccharide Polymers 0.000 claims 2
- 239000005017 polysaccharide Substances 0.000 claims 2
- 239000003586 protic polar solvent Substances 0.000 claims 2
- 239000002904 solvent Substances 0.000 claims 2
- IUSARDYWEPUTPN-OZBXUNDUSA-N (2r)-n-[(2s,3r)-4-[[(4s)-6-(2,2-dimethylpropyl)spiro[3,4-dihydropyrano[2,3-b]pyridine-2,1'-cyclobutane]-4-yl]amino]-3-hydroxy-1-[3-(1,3-thiazol-2-yl)phenyl]butan-2-yl]-2-methoxypropanamide Chemical compound C([C@H](NC(=O)[C@@H](C)OC)[C@H](O)CN[C@@H]1C2=CC(CC(C)(C)C)=CN=C2OC2(CCC2)C1)C(C=1)=CC=CC=1C1=NC=CS1 IUSARDYWEPUTPN-OZBXUNDUSA-N 0.000 claims 1
- 208000031729 Bacteremia Diseases 0.000 claims 1
- 206010006458 Bronchitis chronic Diseases 0.000 claims 1
- 102000014914 Carrier Proteins Human genes 0.000 claims 1
- 108010078791 Carrier Proteins Proteins 0.000 claims 1
- 206010009137 Chronic sinusitis Diseases 0.000 claims 1
- 206010010741 Conjunctivitis Diseases 0.000 claims 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims 1
- 201000009906 Meningitis Diseases 0.000 claims 1
- 206010033078 Otitis media Diseases 0.000 claims 1
- 206010035664 Pneumonia Diseases 0.000 claims 1
- SMNRFWMNPDABKZ-WVALLCKVSA-N [[(2R,3S,4R,5S)-5-(2,6-dioxo-3H-pyridin-3-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl] [[[(2R,3S,4S,5R,6R)-4-fluoro-3,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-hydroxyphosphoryl]oxy-hydroxyphosphoryl] hydrogen phosphate Chemical compound OC[C@H]1O[C@H](OP(O)(=O)OP(O)(=O)OP(O)(=O)OP(O)(=O)OC[C@H]2O[C@H]([C@H](O)[C@@H]2O)C2C=CC(=O)NC2=O)[C@H](O)[C@@H](F)[C@@H]1O SMNRFWMNPDABKZ-WVALLCKVSA-N 0.000 claims 1
- 230000009798 acute exacerbation Effects 0.000 claims 1
- 229910021529 ammonia Inorganic materials 0.000 claims 1
- 206010003246 arthritis Diseases 0.000 claims 1
- 206010006451 bronchitis Diseases 0.000 claims 1
- 235000014633 carbohydrates Nutrition 0.000 claims 1
- 208000007451 chronic bronchitis Diseases 0.000 claims 1
- 201000005547 chronic conjunctivitis Diseases 0.000 claims 1
- 208000027157 chronic rhinosinusitis Diseases 0.000 claims 1
- 229940125807 compound 37 Drugs 0.000 claims 1
- 239000002577 cryoprotective agent Substances 0.000 claims 1
- 238000003745 diagnosis Methods 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 238000005984 hydrogenation reaction Methods 0.000 claims 1
- 238000010324 immunological assay Methods 0.000 claims 1
- 239000003550 marker Substances 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 229910052708 sodium Inorganic materials 0.000 claims 1
- 239000011734 sodium Substances 0.000 claims 1
- 239000000126 substance Substances 0.000 claims 1
- 125000003396 thiol group Chemical group [H]S* 0.000 claims 1
- 229960005486 vaccine Drugs 0.000 claims 1
- 0 CC(*1)OC(C)[C@](*)C1OC Chemical compound CC(*1)OC(C)[C@](*)C1OC 0.000 description 5
- ADUUKKFZJMALKO-BQHSNLCNSA-N CC(C(C([C@H]1O)OC)O)OC1C(O)=O Chemical compound CC(C(C([C@H]1O)OC)O)OC1C(O)=O ADUUKKFZJMALKO-BQHSNLCNSA-N 0.000 description 1
- IOSZEGRLKFATDL-VHJXUHCKSA-N CC(C(C([C@H]1OC)[O-])O)OC1C(O)=O Chemical compound CC(C(C([C@H]1OC)[O-])O)OC1C(O)=O IOSZEGRLKFATDL-VHJXUHCKSA-N 0.000 description 1
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP13175447 | 2013-07-07 | ||
| EP13175447.5 | 2013-07-07 | ||
| EP13183826.0 | 2013-09-10 | ||
| EP13183826.0A EP2845860A1 (en) | 2013-09-10 | 2013-09-10 | Synthetic vaccines against Streptococcus pneumoniae |
| EP13196568 | 2013-12-10 | ||
| EP13196568.3 | 2013-12-10 | ||
| PCT/EP2014/064407 WO2015004041A1 (en) | 2013-07-07 | 2014-07-07 | Synthetic vaccines against streptococcus pneumoniae type 1 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016526564A JP2016526564A (ja) | 2016-09-05 |
| JP2016526564A5 true JP2016526564A5 (enExample) | 2018-04-26 |
| JP6416249B2 JP6416249B2 (ja) | 2018-10-31 |
Family
ID=51257468
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016524767A Active JP6416249B2 (ja) | 2013-07-07 | 2014-07-07 | ストレプトコッカス ニューモニエ１型に対する合成ワクチン |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US10328141B2 (enExample) |
| EP (1) | EP3019513B1 (enExample) |
| JP (1) | JP6416249B2 (enExample) |
| KR (1) | KR102250099B1 (enExample) |
| CN (1) | CN105492454B (enExample) |
| AU (1) | AU2014289342B2 (enExample) |
| BR (1) | BR112016000210A2 (enExample) |
| CA (1) | CA2917365A1 (enExample) |
| HK (1) | HK1224300A1 (enExample) |
| IL (1) | IL243452B (enExample) |
| MX (1) | MX2016000099A (enExample) |
| RU (1) | RU2016103771A (enExample) |
| SG (1) | SG11201600042YA (enExample) |
| WO (1) | WO2015004041A1 (enExample) |
| ZA (1) | ZA201600136B (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11160855B2 (en) | 2014-01-21 | 2021-11-02 | Pfizer Inc. | Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof |
| US10188718B2 (en) * | 2014-12-12 | 2019-01-29 | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. | Vaccines against Streptococcus pneumoniae serotype 4 |
| US20190119313A1 (en) * | 2016-04-14 | 2019-04-25 | Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften E.V. | Improved preparation of vaccines against streptococcus pneumoniae type 3 |
| EP3655943A1 (en) | 2017-07-17 | 2020-05-27 | 3M Innovative Properties Company | Curvature limiting film |
| US20220054632A1 (en) | 2018-12-12 | 2022-02-24 | Glaxosmithkline Biologicals Sa | Modified carrier proteins for o-linked glycosylation |
| JP2025537898A (ja) | 2022-11-22 | 2025-11-20 | ファイザー・インク | コンジュゲートさせた莢膜糖類抗原を含む免疫原性組成物およびその使用 |
| TW202527906A (zh) | 2023-09-14 | 2025-07-16 | 美商輝瑞股份有限公司 | 包含經結合之肺炎鏈球菌莢膜醣抗原之佐劑化致免疫性組成物及其用途 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5153312A (en) * | 1990-09-28 | 1992-10-06 | American Cyanamid Company | Oligosaccharide conjugate vaccines |
| CA2059692C (en) * | 1991-01-28 | 2004-11-16 | Peter J. Kniskern | Pneumoccoccal polysaccharide conjugate vaccine |
| EP2277541A1 (en) * | 2000-06-29 | 2011-01-26 | SmithKline Beecham Biologicals S.A. | Multivalent vaccine composition |
| US20070275007A1 (en) * | 2003-11-05 | 2007-11-29 | The Government Of The United States Of America, Represented By The Secretary Of Health And Human S | Carbohydrate Antigen-Nanoparticle Conjugates and Uses Thereof as Antimetastatic Agents in Treating Cancer |
| EP1885734B1 (en) * | 2005-05-06 | 2015-01-14 | Novartis AG | Immunogens for meningitidis-a vaccines |
| WO2011133227A2 (en) | 2010-04-23 | 2011-10-27 | Ancora Pharmaceuticals Inc. | Synthetic oligosaccharides for staphyloccocus vaccine |
| US8716469B2 (en) | 2010-04-27 | 2014-05-06 | Ancora Pharmaceuticals, Inc. | Synthetic oligosaccharides for Moraxella vaccine |
-
2014
- 2014-07-07 RU RU2016103771A patent/RU2016103771A/ru not_active Application Discontinuation
- 2014-07-07 JP JP2016524767A patent/JP6416249B2/ja active Active
- 2014-07-07 CA CA2917365A patent/CA2917365A1/en not_active Abandoned
- 2014-07-07 KR KR1020167003282A patent/KR102250099B1/ko active Active
- 2014-07-07 CN CN201480046993.4A patent/CN105492454B/zh active Active
- 2014-07-07 WO PCT/EP2014/064407 patent/WO2015004041A1/en not_active Ceased
- 2014-07-07 US US14/903,118 patent/US10328141B2/en active Active
- 2014-07-07 EP EP14744787.4A patent/EP3019513B1/en active Active
- 2014-07-07 AU AU2014289342A patent/AU2014289342B2/en active Active
- 2014-07-07 MX MX2016000099A patent/MX2016000099A/es unknown
- 2014-07-07 BR BR112016000210A patent/BR112016000210A2/pt not_active Application Discontinuation
- 2014-07-07 SG SG11201600042YA patent/SG11201600042YA/en unknown
- 2014-07-07 HK HK16112653.5A patent/HK1224300A1/zh unknown
-
2016
- 2016-01-03 IL IL243452A patent/IL243452B/en active IP Right Grant
- 2016-01-07 ZA ZA2016/00136A patent/ZA201600136B/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016526564A5 (enExample) | ||
| RU2016103771A (ru) | Синтетические вакцины против streptococcus pneumoniae 1-го типа | |
| JP2016512425A5 (enExample) | ||
| KR102480429B1 (ko) | 스트렙토코커스 뉴모니에 혈청형 8에 대한 백신 | |
| JP2010132925A5 (enExample) | ||
| TWI633112B (zh) | 醣類－醣脂類結合性疫苗 | |
| Gauthier et al. | Non-stoichiometric O-acetylation of Shigella flexneri 2a O-specific polysaccharide: synthesis and antigenicity | |
| JP2008540398A5 (enExample) | ||
| JP2017532321A5 (enExample) | ||
| CA2797052A1 (en) | Synthetic oligosaccharides for staphyloccocus vaccine | |
| CN107709343B (zh) | 针对肺炎链球菌血清型5的疫苗 | |
| JP2020514414A (ja) | 糖結合タンパク質を隔離する糖ポリマー | |
| JP2019508468A (ja) | 新規の多糖体−タンパク質コンジュゲート及びそれを得る方法 | |
| CN105829342A (zh) | 铜绿假单胞菌的psl胞外多糖的合成寡糖亚基及其用途 | |
| Wang et al. | Total synthesis and structural studies of zwitterionic Bacteroides fragilis polysaccharide A1 fragments | |
| Paul et al. | Total synthesis of a structurally complex tetrasaccharide repeating unit of Vibrio cholerae O43 | |
| ES2360862T3 (es) | Materiales y procedimientos para la estimulación del sistema inmunitario. | |
| CN103755840B (zh) | 一种含1,2,3-三氮唑的菊糖衍生物及其制备方法 | |
| Morelli et al. | Synthesis and biological evaluation of a trisaccharide repeating unit derivative of Streptococcus pneumoniae 19A capsular polysaccharide | |
| CN107224577A (zh) | 一种基于3型肺炎链球菌荚膜多糖的寡糖缀合物及其制备方法与应用 | |
| JP2017537941A5 (enExample) | ||
| Giuliani et al. | Exploring calixarene-based clusters for efficient functional presentation of Streptococcus pneumoniae saccharides | |
| JP2016513747A5 (enExample) | ||
| EP2986986A2 (en) | Oligosaccharide conjugates and methods of use | |
| CN106084037B (zh) | 一种炭疽杆菌荚膜表面三糖缀合物及其制备方法和应用 |